Recent studies have demonstrated enhanced anticancer effects of combination therapy consisting of camptothecin derivatives and HDAC inhibitors. To exploit this synergy in a single active compound, we designed new dual-acting multivalent molecules simultaneously targeting topoisomerase I and HDAC. In particular, a selected compound containing a camptothecin and the psammaplin A scaffold showed a broad spectrum of antiproliferative activity, with IC50values in the nanomolar range. Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.
Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors / R. Cincinelli, L. Musso, R. Artali, M. Guglielmi, E. Bianchino, F. Cardile, F. Colelli, C. Pisano, S. Dallavalle. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 143(2018), pp. 2005-2014.
Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors
R. Cincinelli;L. Musso;S. Dallavalle
2018
Abstract
Recent studies have demonstrated enhanced anticancer effects of combination therapy consisting of camptothecin derivatives and HDAC inhibitors. To exploit this synergy in a single active compound, we designed new dual-acting multivalent molecules simultaneously targeting topoisomerase I and HDAC. In particular, a selected compound containing a camptothecin and the psammaplin A scaffold showed a broad spectrum of antiproliferative activity, with IC50values in the nanomolar range. Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.File | Dimensione | Formato | |
---|---|---|---|
2018 CPt-psammaplina.pdf
Open Access dal 29/12/2019
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
950.09 kB
Formato
Adobe PDF
|
950.09 kB | Adobe PDF | Visualizza/Apri |
1-s2.0-S0223523417309169-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.18 MB
Formato
Adobe PDF
|
1.18 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.